@article{MTMT:34397560,
	title = {Immunellenőrzőpont-gátlók a cervix- és endometriumcarcinoma kezelésének gyakorlatában - összefoglaló a Debreceni Egyetem Nőgyógyászati Onkológiai Tanszék betegeinek terápiás eredményeiről},
	url = {https://m2.mtmt.hu/api/publication/34397560},
	author = {Árokszállási, Anita and Molnár, Szabolcs and Damjanovich, Péter Gábor and Lukács, János and Kovács, Ilona and Molnár, Sarolta and Póka, Róbert and Hernádi, Zoltán and Lampé, Rudolf and Krasznai, Zoárd Tibor},
	journal-iso = {MAGYAR ONKOLÓGIA},
	journal = {MAGYAR ONKOLÓGIA},
	volume = {67},
	unique-id = {34397560},
	issn = {0025-0244},
	year = {2023},
	eissn = {2060-0399},
	pages = {9-10},
	orcid-numbers = {Lampé, Rudolf/0000-0002-8230-7692}
}

@article{MTMT:32789688,
	title = {Expression of Growth Hormone-Releasing Hormone and Its Receptor Splice Variants in Primary Human Endometrial Carcinomas: Novel Therapeutic Approaches},
	url = {https://m2.mtmt.hu/api/publication/32789688},
	author = {Szabó, Zsuzsanna and Juhász, Éva and V. Schally, Andrew and Dezső, Balázs and Huga, Sandor and Hernádi, Zoltán and Halmos, Gábor and Kiss, Csongor},
	doi = {10.3390/molecules27092671},
	journal-iso = {MOLECULES},
	journal = {MOLECULES},
	volume = {27},
	unique-id = {32789688},
	issn = {1420-3049},
	abstract = {Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of various tumors, including endometrial carcinomas (EC). However, tumoral receptors that mediate the antiproliferative effects of GHRH antagonists in human ECs have not been fully characterized. In this study, we investigated the expression of mRNA for GHRH and splice variants (SVs) of GHRH receptors (GHRH-R) in 39 human ECs and in 7 normal endometrial tissue samples using RT-PCR. Primers designed for the PCR amplification of mRNA for the full length GHRH-R and SVs were utilized. The PCR products were sequenced, and their specificity was confirmed. Nine ECs cancers (23%) expressed mRNA for SV1, three (7.7%) showed SV2 and eight (20.5%) revealed mRNA for SV4. The presence of SVs for GHRH-Rs could not be detected in any of the normal endometrial tissue specimens. The presence of specific, high affinity GHRH-Rs was also demonstrated in EC specimens using radioligand binding studies. Twenty-four of the investigated thirty-nine tumor samples (61.5%) and three of the seven corresponding normal endometrial tissues (42.9%) expressed mRNA for GHRH ligand. Our findings suggest the possible existence of an autocrine loop in EC based on GHRH and its tumoral SV receptors. The antiproliferative effects of GHRH antagonists on EC are likely to be exerted in part by the local SVs and GHRH system.},
	year = {2022},
	eissn = {1420-3049}
}

@article{MTMT:32049244,
	title = {Multimodális hiperspektroszkópia – előrelépés a digitális technológia felé a méhnyakszűrésben = Multimodal hyperspectroscopy – the use of digital technology in cervical cancer screening},
	url = {https://m2.mtmt.hu/api/publication/32049244},
	author = {Krasznai, Zoárd Tibor and Bagoly, Zsuzsa and Nagy, Eszter and Farkas, Zsolt and Póka, Róbert and Török, Péter and Lampé, Rudolf and Hernádi, Zoltán},
	doi = {10.1556/650.2021.32096},
	journal-iso = {ORV HETIL},
	journal = {ORVOSI HETILAP},
	volume = {162},
	unique-id = {32049244},
	issn = {0030-6002},
	abstract = {Összefoglaló. Bevezetés: Bevezetés: A citológiai alapú méhnyakrákszűrés átmeneti kategóriáinak optimális menedzselése a humán papillomavírus (HPV) szűrése és tipizálása ellenére jelenleg is kihívás. Vizsgálatunk célja a modern cervixspektroszkópiának (multimodális hiperspektroszkópia - MHS), egy azonnali eredményt nyújtó, digitális technológiára épülő módszernek a vizsgálata volt a citológiai alapú méhnyakszűrés találati biztonságának javítására. Betegek és módszer: Vizsgálatainkat 208, 18 és 75 év közötti nőbeteg bevonásával végeztük, akiknél már indikálásra került valamely, a méhnyakon végzendő műtét, citológiai eredményük rendelkezésre állt (a HPV-tesztet, amennyiben nem történt meg, elvégeztük), valamint valamennyi betegnél elvégeztük a műtét előtt az MHS-vizsgálatot. A szövettani mintavétel 166 betegnél történt meg. Eredmények: A citológiai vizsgálatot (az összes betegre tekintve) magas álpozitív arány jellemezte (69,28%), amely megfigyelések mindenképpen utalnak az újabb komponens alkalmazásának igényére a triázsban. Az összes citológiai kategóriára nézve az MHS-eredmények közül kiemelendő az álnegatív leletek rendkívül alacsony aránya (3/166 = 1,8%), mely a HPV-teszt esetén ennél magasabb volt (11/165 = 6,66%). A spektroszkópiás vizsgálat álpozitív aránya ugyanakkor kedvezőtlenebbnek bizonyult (91/166 = 54,81%) a HPV-vizsgálat álpozitív arányánál (40/165 = 24,24%). Az atípusos laphámsejt (ASC-US/ASC-H) citológiai kategória esetén a spektroszkópia álnegatív eredményeinek aránya (3/126 = 2,38%) szintén kedvezőbb volt, mint a HPV-vizsgálaté (9/126 = 7,14%). A cervicalis intraepithelialis neoplasia-2 vagy súlyosabb fokozatú hámelváltozások azonosításában a spektroszkópia szenzitivitása 94% (95% CI = 0,84-0,99), specificitása 22% (95% CI = 0,15-0,31), negatív prediktív értéke 90% (95% CI = 0,73-0,98), pozitív prediktív értéke 34% (95% CI = 0,26-0,43) volt (p = 0,00130). Következtetés: Az MHS fejlett innovatív technológián alapuló, azonnali eredményt adó vizsgálóeljárás, amely kiemelkedően alacsony álnegatív eredménye miatt nagy segítséget nyújt a citológiai eltéréssel rendelkező betegek további vizsgálatában. Orv Hetil. 2021; 162(20): 790-799.Despite the use of human papillomavirus (HPV) testing, the management of the transitional categories of cytology-based screening still remains a challenge. The modern multimodal hyperspectroscopy (MHS) of the cervix is a novel digital technology based on artificial intelligence, providing an instant result in the assessment of cytology-based screening abnormalities.208 women (age 18-75) were enrolled. The patients already had cytology results and an operation on the cervix indicated at the time of inclusion. HPV and the hyperspectroscopy examination was performed pre-operatively. The pre-indicated operation was performed on 166 patients.Cytology-based screening alone (in the category of all patients) resulted in a high false-positive rate (69.28%). In this category, the MHS had an outstanding false-negative rate (3/166 = 1.80%) compared to the HPV (11/165 = 6.66%). The false-positive rate of the spectroscopy examination (91/166 = 54.81%) was higher than that of the HPV testing (40/165 = 24.24%). In the atypical squamous cell (ASC-US/ASC-H) category, the false-negative rate of the spectroscopy (3/126 = 2.38%) was also lower than that of the HPV test (9/126 = 7.14%). In the detection of high-grade abnormalities (cervical intraepithelial neoplasia 2 and worse), the spectroscopy had a 94% sensitivity (95% CI = 0.84-0.99), with a 22% specificity (95% CI = 0.15-0.31), an 90% negative predictive value (95% CI = 0.73-0.98), and a 34% positive predictive value (95% CI = 0.26-0.43) (p = 0.00130).In the case of cytological abnormality, the MHS provides an immediate result based on advanced digital technology, and because of its outstanding false negative rate it is a great aid and should be considered in the triage of such patients. Orv Hetil. 2021; 162(20): 790-799.},
	keywords = {SPECTROSCOPY; Artificial intelligence; human papillomavirus; Cervical Intraepithelial Neoplasia; Mesterséges intelligencia; spektroszkópia; ASC-US; cervicalis intraepithelialis neoplasia},
	year = {2021},
	eissn = {1788-6120},
	pages = {790-799},
	orcid-numbers = {Bagoly, Zsuzsa/0000-0001-5314-5607; Lampé, Rudolf/0000-0002-8230-7692}
}

@article{MTMT:32587488,
	title = {The usability of CA 125 and HE4 tumour markers in the prediction and verification of complete tumour resection and progression free survival in advanced ovarian cancer patients},
	url = {https://m2.mtmt.hu/api/publication/32587488},
	author = {Molnár, Szabolcs and Maka, Eszter and Bagoly, Zsuzsa and Lampé, Rudolf and Póka, Róbert and Hernádi, Zoltán and Krasznai, Zoárd Tibor},
	journal-iso = {INT J GYNECOL CANCER},
	journal = {INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER},
	volume = {29},
	unique-id = {32587488},
	issn = {1048-891X},
	year = {2019},
	eissn = {1525-1438},
	pages = {P134},
	orcid-numbers = {Bagoly, Zsuzsa/0000-0001-5314-5607; Lampé, Rudolf/0000-0002-8230-7692}
}

@article{MTMT:27558160,
	title = {Cell adhesion molecule profiles, proliferation activity and p53 expression in advanced epithelial ovarian cancer induced malignant ascites-Correlation of tissue microarray and cytology microarray},
	url = {https://m2.mtmt.hu/api/publication/27558160},
	author = {Tóth, László József and Nagy, Bence and Méhes, Gábor and Laszlo, Eszter and Molnar, Peter Pal and Póka, Róbert and Hernádi, Zoltán},
	doi = {10.1016/j.prp.2018.05.014},
	journal-iso = {PATHOL RES PRACT},
	journal = {PATHOLOGY RESEARCH AND PRACTICE},
	volume = {214},
	unique-id = {27558160},
	issn = {0344-0338},
	year = {2018},
	eissn = {1618-0631},
	pages = {978-985}
}

@article{MTMT:3351689,
	title = {Negative PARP immunhistochemistry as a predictor of platinum sensitivity in ovarian cancer},
	url = {https://m2.mtmt.hu/api/publication/3351689},
	author = {Póka, Róbert and Molnár, S and Baráth, L and Lukács, János and Lampé, Rudolf and Krasznai, Zoárd Tibor and Hernádi, Zoltán and Méhes, Gábor},
	doi = {10.1097/01.IGC.0000527296.86225.87},
	journal-iso = {INT J GYNECOL CANCER},
	journal = {INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER},
	volume = {27},
	unique-id = {3351689},
	issn = {1048-891X},
	year = {2017},
	eissn = {1525-1438},
	pages = {524-525},
	orcid-numbers = {Lampé, Rudolf/0000-0002-8230-7692}
}

@article{MTMT:3312980,
	title = {Javaslat a hazai méhnyakszűrési eljárásrend korszerűsítésére},
	url = {https://m2.mtmt.hu/api/publication/3312980},
	author = {Koiss, R and Boncz, Imre and Hernádi, Zoltán and Szentirmay, Zoltán},
	doi = {10.1556/650.2017.30896},
	journal-iso = {ORV HETIL},
	journal = {ORVOSI HETILAP},
	volume = {158},
	unique-id = {3312980},
	issn = {0030-6002},
	year = {2017},
	eissn = {1788-6120},
	pages = {2062-2067},
	orcid-numbers = {Boncz, Imre/0000-0003-3699-6236}
}

@article{MTMT:3254635,
	title = {Nuclear beta-catenin positivity as a predictive marker of long-term survival in advanced epithelial ovarian cancer},
	url = {https://m2.mtmt.hu/api/publication/3254635},
	author = {Nagy, Bence and Tóth, László József and Molnár, Péter and Méhes, Gábor and Thurzó, László and Póka, Róbert and Hernádi, Zoltán},
	doi = {10.1016/j.prp.2017.05.011},
	journal-iso = {PATHOL RES PRACT},
	journal = {PATHOLOGY RESEARCH AND PRACTICE},
	volume = {213},
	unique-id = {3254635},
	issn = {0344-0338},
	year = {2017},
	eissn = {1618-0631},
	pages = {915-921}
}

@article{MTMT:3244649,
	title = {Intention-to-Treat Analysis of Radical Trachelectomy for Early-Stage Cervical Cancer With Special Reference to Oncologic Failures: Single-Institutional Experience in Hungary},
	url = {https://m2.mtmt.hu/api/publication/3244649},
	author = {Póka, Róbert and Molnár, Szabolcs and Daragó, Péter and Lukács, János and Lampé, Rudolf and Krasznai, Zoárd Tibor and Hernádi, Zoltán},
	doi = {10.1097/IGC.0000000000001048},
	journal-iso = {INT J GYNECOL CANCER},
	journal = {INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER},
	volume = {27},
	unique-id = {3244649},
	issn = {1048-891X},
	abstract = {OBJECTIVE:
		The aim of our study was to evaluate clinical and pathological data in order 
		to draw eligibility criteria for oncologically sufficient radical trachelectomy 
		(RT) in early-stage cervical cancer. Reviewing all cases of attempted RT 
		performed at our unit, we focused attention on prognostic indicators of the 
		need for additional oncologic treatment following RT. The analysis was 
		extended by extensive literature review to include previously published 
		cases of oncologic failures.
		METHODS:
		The authors retrospectively analyzed data of patients who underwent RT at 
		the Department of Obstetrics and Gynecology, University of Debrecen. 
		Electronic records and case notes of RT cases were reviewed to determine 
		the incidence of abdominal and vaginal route, distribution of 
		clinicopathologic data, and follow-up results of individual cases. Individual 
		procedures were categorized as oncologically insufficient if additional 
		oncologic treatment was necessary following RT. Theoretical eligibility 
		criteria for RT in early-stage cervical cancer were determined retrospectively 
		by selecting prognostic features that were associated with oncologic 
		insufficiency from clinicopathologic indicators of the complete series.
		RESULTS:
		Twenty-four cases of RT were performed by the authors, 15 vaginal RTs with 
		laparoscopic pelvic lymphadenectomy and 9 abdominal RTs with open pelvic 
		lymphadenectomy. Fifteen of 24 cases proved oncologically sufficient. 
		Three cases required immediate conversion to radical hysterectomy because 
		of positive sentinel nodes and/or positive isthmic disc on frozen section. In 
		further 5 cases, final pathology results indicated additional oncologic 
		treatment, that is, radical hysterectomy (n = 2), chemoradiotherapy (n = 2), 
		or chemotherapy (n = 1). One patient among immediately converted cases 
		and another 3 among those who required additional oncologic treatment 
		died of their disease later. There were no other cases of recurrences over a 
		median follow-up of 34 months (range, 12-188 months). Factors that may 
		predict oncologic insufficiency of RT were stage IB1 or greater, tumor size of 
		greater than 2 cm in 1 dimension or greater than 15 mm in 3 dimensions, G3, 
		nonsquamous/adeno histological type, stromal invasion of greater than 9 
		mm, and lymphovascular space involvement in the primary tumor.
		CONCLUSIONS:
		Most cases of oncologically insufficient RTs have significant risk features 
		that can be identified preoperatively. There is a need for more 
		clinicopathologic data on oncologic failure of RT cases in order to improve 
		patient selection.},
	keywords = {Cervical cancer; Clinicopathologic predictors; Fertility-sparing surgery; Oncologic failure},
	year = {2017},
	eissn = {1525-1438},
	pages = {1438-1445},
	orcid-numbers = {Lampé, Rudolf/0000-0002-8230-7692}
}

@{MTMT:3189296,
	title = {Humán papillomavírus (HPV). Védőoltások.},
	url = {https://m2.mtmt.hu/api/publication/3189296},
	author = {Hernádi, Zoltán},
	booktitle = {A nőgyógyászat kézikönyve},
	unique-id = {3189296},
	year = {2016},
	pages = {484-499}
}